Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sasaki, S. [1 ]
Oikado, K. [2 ]
Saito, Y. [3 ]
Tominaga, J. [4 ]
Sata, M. [5 ]
Sakai, F. [6 ]
Kato, T. [7 ]
Iwasawa, T. [8 ]
Kenmotsu, H. [9 ]
Kusumoto, M. [10 ]
Baba, T. [11 ]
Endo, M. [12 ]
Fujiwara, Y. [13 ]
Sugiura, H. [14 ]
Yanagawa, N. [15 ]
Ito, Y. [16 ]
Sakamoto, T. [16 ]
Ohe, Y. [17 ]
Kuwano, K. [18 ]
机构：
[1] Juntendo Univ, Urayasu Hosp, Resp Med, Chiba, Japan
[2] Canc Inst Hosp, Dept Diagnost Imaging, Tokyo, Japan
[3] Nippon Med Coll Hosp, Dept Pulm Med & Oncol, Tokyo, Japan
[4] Tohoku Univ, Sch Med, Dept Diagnost Radiol, Sendai, Miyagi, Japan
[5] Jichi Med Univ Hosp, Div Pulm Med, Shimotsuke, Tochigi, Japan
[6] Saitama Med Univ, Int Med Ctr, Dept Diagnost Radiol, Hidaka, Japan
[7] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan
[8] Kanagawa Cardiovasc & Resp Ctr, Dept Radiol, Yokohama, Kanagawa, Japan
[9] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan
[10] Natl Canc Ctr, Dept Diagnost Radiol, Tokyo, Japan
[11] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[12] Shizuoka Canc Ctr, Div Diagnost Radiol, Nagaizumi, Shizuoka, Japan
[13] Mitsui Mem Hosp, Dept Resp Med, Tokyo, Japan
[14] Keio Univ, Sch Med, Dept Diagnost Radiol, Tokyo, Japan
[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Radiol, Tokyo, Japan
[16] Ono Pharmaceut Co Ltd, Pharmacovigilance Div, Osaka, Japan
[17] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[18] Jikei Univ, Sch Med, Dept Internal Med, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1299P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
    Sander Bins
    Edwin A. Basak
    Samira el Bouazzaoui
    Stijn L. W. Koolen
    E. Oomen – de Hoop
    Cor H. van der Leest
    Astrid A. M. van der Veldt
    Stefan Sleijfer
    Reno Debets
    Ron H. N. van Schaik
    Joachim G. J. V. Aerts
    Ron H. J. Mathijssen
    British Journal of Cancer, 2018, 118 : 1296 - 1301
  • [42] Prognostic factors for nivolumab monotherapy in postoperative recurrence of non-small cell lung cancer
    Inoue, Takashi
    Ishihama, Hiromi
    Tachibana, Taimei
    Imamura, Nobuhiro
    Nonaka, Yuuto
    Ito, Yoshiyuki
    Araki, Osamu
    Sumiko, Maeda
    Chida, Masayuki
    ANNALS OF ONCOLOGY, 2021, 32 : S334 - S334
  • [43] EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
    Dixmier, A.
    Debieuvre, D.
    Raspaud, C.
    Auliac, J. B.
    Benoit, N.
    Bombaron, P.
    Asselain, B.
    Dumont, A.
    Lamoureux, P.
    Goyard, N.
    Moro-Sibilot, D.
    Perol, M.
    Barlesi, F.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2018, 29 : 532 - 532
  • [44] Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
    Bins, Sander
    Basak, Edwin A.
    el Bouazzaoui, Samira
    Koolen, Stijn L. W.
    Hoop, E. Oomen-de
    van der Leest, Cor H.
    van der Veldt, Astrid A. M.
    Sleijfer, Stefan
    Debets, Reno
    van Schaik, Ron H. N.
    Aerts, Joachim G. J. V.
    Mathijssen, Ron H. J.
    BRITISH JOURNAL OF CANCER, 2018, 118 (10) : 1296 - 1301
  • [45] Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
    Yamaguchi, Teppei
    Shimizu, Junichi
    Shigematsu, Fumie
    Watanabe, Naohiro
    Hasegawa, Takaaki
    Horio, Yoshitsugu
    Inaba, Yoshitaka
    Fujiwara, Yutaka
    JOURNAL OF THORACIC DISEASE, 2024, 16 (05) : 3371 - 3380
  • [46] Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
    Takano, T
    Ohe, Y
    Kusumoto, M
    Tateishi, U
    Yamamoto, S
    Nokihara, H
    Yamamoto, N
    Sekine, I
    Kunitoh, H
    Tamura, T
    Kodama, T
    Saijo, N
    LUNG CANCER, 2004, 45 (01) : 93 - 104
  • [47] Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    Kurishima, Koichi
    Nakamura, Ryota
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Ohara, Gen
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2671 - 2674
  • [48] Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
    Kato M.
    Shukuya T.
    Takahashi F.
    Mori K.
    Suina K.
    Asao T.
    Kanemaru R.
    Honma Y.
    Muraki K.
    Sugano K.
    Shibayama R.
    Koyama R.
    Shimada N.
    Takahashi K.
    BMC Cancer, 14 (1)
  • [49] T cell immunity in interstitial lung disease with non-small cell lung cancer patients
    Isono, Tomomi
    Iwahori, Kota
    Yanagawa, Masahiro
    Yamamoto, Yoko
    Tone, Mari
    Haruna, Miya
    Hirata, Michinari
    Fukui, Eriko
    Kimura, Toru
    Kanou, Takashi
    Ose, Naoko
    Funaki, Soichiro
    Takeda, Yoshito
    Morii, Eiichi
    Kumanogoh, Atsushi
    Shintani, Yasushi
    Wada, Hisashi
    LUNG CANCER, 2023, 182
  • [50] Independent review of fatal interstitial lung disease (ILD) in TRIBUTE:: paclitaxel plus carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC).
    Gandara, D. R.
    Yoneda, K.
    Shelton, D.
    Beckett, L. A.
    Ramies, D. A.
    Bloss, J.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 381S - 381S
12345